Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use Sabrina BagaglioCaterina Uberti-FoppaGiulia Morsica Leading Article 12 May 2017 Pages: 1043 - 1055
Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects Mathurin FlamantJosselin RigaillXavier Roblin Leading Article 18 May 2017 Pages: 1057 - 1068
Advanced Analgesic Drug Delivery and Nanobiotechnology Nicoleta StoiceaJuan Fiorda-DiazSergio D. Bergese Review Article Open access 03 May 2017 Pages: 1069 - 1076
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives Matthew S. FarinaKevin T. LundgrenJoaquim Bellmunt Review Article 11 May 2017 Pages: 1077 - 1089
Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor Joleen M. HubbardAxel Grothey Review Article 01 June 2017 Pages: 1091 - 1103
Ustekinumab: A Review in Moderate to Severe Crohn’s Disease Yvette N. LambSean T. Duggan Adis Drug Evaluation 20 May 2017 Pages: 1105 - 1114
Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors David A. Schoenfeld Letter to the Editor 01 June 2017 Pages: 1137 - 1138
Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors” Stefan MichielsEverardo D. SaadMarc Buyse Letter to the Editor 01 June 2017 Pages: 1139 - 1140
Erratum to: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis Bruno GelonezeJosé Carlos de Lima-JúniorLício A. Velloso Erratum 18 May 2017 Pages: 1141 - 1141
